Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nitrogen-containing Heterocyclic Derivatives of 1,3-Thiazolidine-2,4- Diones as Dual Anti-inflammatory and Anti-oxidant Agents and their Docking Studies

Author(s): Priyanka Srivastava, Ghanshyam Teli and Pooja A. Chawla*

Volume 20, Issue 7, 2023

Published on: 07 October, 2022

Page: [894 - 915] Pages: 22

DOI: 10.2174/1570180819666220523142245

Price: $65

conference banner
Abstract

Aim: The aim of this study was to carry out synthesis and characterization of nitrogencontaining heterocyclic derivatives of 1,3-thiazolidine-2,4-diones as dual anti-inflammatory and antioxidant agents and their docking studies.

Background: Inflammation is a protective mechanism of our body to reduce injury and infection by microorganisms. The COX-2 enzyme is responsible for the production of prostaglandins (PG1), which are responsible for pain, fever, and a variety of other inflammatory symptoms. Reactive oxygen species (ROS) are important signalling molecules during inflammatory diseases. In an inflammatory state, polymorphonuclear neutrophils (PMNs) produce oxidative stress, which causes inter-endothelium junctions to open and the transfer of inflammatory cells over the endothelial barrier to increase. Tissue damage is caused by these inflammatory cells.

Objective: The objective was to club thiazolidinediones with benzimidazole, triazole, and indole to achieve an enhanced anti-inflammatory effect.

Methods: In the current report, we have synthesized three new series of indole/ benzimidazole/benzotriazole clubbed with 5-arylidene-2,4-thiazolidinediones. The synthesized compounds were tested for in vivo anti-inflammatory activity using a carrageenan-induced rat paw edema model and in vitro antioxidant activity using 2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP) and hydrogen peroxide methods.

Results: The results demonstrated that the compound PC-5 exhibited significant anti-inflammatory activity with 61.9% inhibition in comparison to the standard drug diclofenac sodium (71.4% inhibition) after 3h. The compound PC-5 exerted the highest antioxidant activity with an IC50 value of 24.68 μM amongst all synthesized compounds. Acute toxicity was also evaluated for all synthesized compounds, and the results indicated that all evaluated compounds were nontoxic in animals. The replacement of benzotriazole with benzimidazole and indole moieties diminished the anti-inflammatory activity. The hydroxysubstituted arylidene showed higher activity than methoxy, chloro substituted arylidene-2,4- thiazolididiones. Docking studies revealed that the compound PC-5 showed higher inhibition activity against the COX-2 receptor rather than COX-1. The ADME properties were also assessed that showed no violation of Lipinski’s rule and no toxicity.

Conclusion: The substituents were found to exert varied activity. The docking studies revealed that the compounds showed lesser binding energy with COX-1 as compared to standard drug diclofenac. Moreover, the binding with COX-2 exhibited more binding energy, thereby proving to have specific COX2 inhibitory activity. All synthesised compounds have shown good antioxidant activity in addition to antiinflammatory activity. PC-5, PC-4, PB-5, PB-4, PA-5, and PA-4 were found to have increased antioxidant activity. Because of the presence of an electron-releasing hydroxyl group, PC-5 has proven to be a highly potent antioxidant agent.

Keywords: Synthesis, 2, 4-thiazolididione, indole, benzimidazole, benzotriazole, anti-oxidant activity, anti-inflammatory activity.

« Previous Next »
Graphical Abstract

[1]
Mangasuli, S.N.; Managutti, P.B.; Hosamani, K.M. Anti-inflammatory activity of novel (5Z)-3-(2-(2-oxo-2H-chromen-4-yloxy) ethyl)-5-benzylidenethiazolidine-2, 4-dione derivatives: An approach to microwave synthesis. Chemical Data Collections, 2020, 30, 100555.
[http://dx.doi.org/10.1016/j.cdc.2020.100555]
[2]
Abdelall, E.K.A.; Lamie, P.F.; Ahmed, A.K.M.; El-Nahass, E.S. COX-1/COX-2 inhibition assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core. Bioorg. Chem., 2019, 86, 235-253.
[http://dx.doi.org/10.1016/j.bioorg.2019.01.031] [PMID: 30716621]
[3]
Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Hénichart, J.P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett., 2002, 12(5), 779-782.
[http://dx.doi.org/10.1016/S0960-894X(02)00013-6] [PMID: 11859001]
[4]
Abdelall, E.K.; Kamel, G.M. Synthesis of new thiazolo-celecoxib analogues as dual cyclooxygenase-2/15-lipoxygenase inhibitors: Determination of regio-specific different pyrazole cyclization by 2D NMR. Eur. J. Med. Chem., 2016, 118, 250-258.
[http://dx.doi.org/10.1016/j.ejmech.2016.04.049] [PMID: 27131067]
[5]
Allison, M.C.; Howatson, A.G.; Torrance, C.J.; Lee, F.D.; Russell, R.I. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1992, 327(11), 749-754.
[http://dx.doi.org/10.1056/NEJM199209103271101] [PMID: 1501650]
[6]
Perrone, M.G.; Lofrumento, D.D.; Vitale, P.; De Nuccio, F.; La Pesa, V.; Panella, A.; Calvello, R.; Cianciulli, A.; Panaro, M.A.; Scilimati, A. Selective cyclooxygenase-1 inhibition by p6 and gastrotoxicity: Preliminary investigation. Pharmacology, 2015, 95(1-2), 22-28.
[http://dx.doi.org/10.1159/000369826] [PMID: 25591798]
[7]
Tanaka, A.; Hase, S.; Miyazawa, T.; Takeuchi, K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: A key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther., 2002, 300(3), 754-761.
[http://dx.doi.org/10.1124/jpet.300.3.754] [PMID: 11861778]
[8]
Micklewright, R.; Lane, S.; Linley, W.; McQuade, C.; Thompson, F.; Maskrey, N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment. Pharmacol. Ther., 2003, 17(3), 321-332.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01454.x] [PMID: 12562444]
[9]
Irfan, M. Selective cyclooxygenase-2 inhibitors: A review of recent chemical scaffolds with promising anti-inflammatory and COX-2 inhibitory activities. Med. Chem. Res., 2020, 29(5), 809-830.
[http://dx.doi.org/10.1007/s00044-020-02528-1]
[10]
Mittal, M.; Siddiqui, M.R.; Tran, K.; Reddy, S.P.; Malik, A.B. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal., 2014, 20(7), 1126-1167.
[http://dx.doi.org/10.1089/ars.2012.5149] [PMID: 23991888]
[11]
Clark, R.; Kupper, T. Old meets new: The interaction between innate and adaptive immunity. J. Invest. Dermatol., 2005, 125(4), 629-637.
[http://dx.doi.org/10.1111/j.0022-202X.2005.23856.x] [PMID: 16185260]
[12]
Beckman, J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol., 1996, 9(5), 836-844.
[http://dx.doi.org/10.1021/tx9501445] [PMID: 8828918]
[13]
Youssef, A.M.; White, M.S.; Villanueva, E.B.; El-Ashmawy, I.M.; Klegeris, A. Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorg. Med. Chem., 2010, 18(5), 2019-2028.
[http://dx.doi.org/10.1016/j.bmc.2010.01.021] [PMID: 20138770]
[14]
Chawla, P.; Garg, P.; Panjwani, D.; Saraf, S. Synthesis of some novel 5-substituted arylidene–2, 4–thiazolidinediones as bioactive agents. International Journal of Pharmaceutical Sciences and Nanotechnology, 2011, 4(1), 1373-1378.
[http://dx.doi.org/10.37285/ijpsn.2011.4.1.10]
[15]
Sharma, P.; Reddy, T.S.; Kumar, N.P.; Senwar, K.R.; Bhargava, S.K.; Shankaraiah, N. Conventional and microwave-assisted synthesis of new 1H-benzimidazole-thiazolidinedione derivatives: A potential anticancer scaffold. Eur. J. Med. Chem., 2017, 138, 234-245.
[http://dx.doi.org/10.1016/j.ejmech.2017.06.035] [PMID: 28668476]
[16]
Bansal, G.; Thanikachalam, P.V.; Maurya, R.K.; Chawla, P.; Ramamurthy, S. An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. J. Adv. Res., 2020, 23, 163-205.
[http://dx.doi.org/10.1016/j.jare.2020.01.008] [PMID: 32154036]
[17]
Ankush, G.; Pooja, C.; Shubhini, S.A. Syntheses of some novel 5-Substituted-Arylidene-3-Substituted-Benzyl-Thiazolidine-2, 4-Dione Analogues as Anti-Hyperglycemic Agents, Int. J. Drug Dev. & Res, 2012, 4(3), 141-146.
[18]
Bansal, G.; Singh, S.; Monga, V.; Thanikachalam, P.V.; Chawla, P. Synthesis and biological evaluation of thiazolidine-2,4-dione-pyrazole conjugates as antidiabetic, anti-inflammatory and antioxidant agents. Bioorg. Chem., 2019, 92, 103271.
[http://dx.doi.org/10.1016/j.bioorg.2019.103271] [PMID: 31536952]
[19]
Ranjan Srivastava, A.; Bhatia, R.; Chawla, P. Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives. Bioorg. Chem., 2019, 89, 102993.
[http://dx.doi.org/10.1016/j.bioorg.2019.102993] [PMID: 31129500]
[20]
Shukla, K.S.; Pandey, S.; Chawla, P. Synthesis of Some 5-(substituted benzylidene-2, 4-dioxothiazolidin-3-yl) benzoic Acid Derivatives by Conventional and Microwave-assisted Methods and Evaluation of their Potential as Antimicrobial Agents. Antiinfect. Agents, 2019, 17(2), 115-129.
[http://dx.doi.org/10.2174/2211352516666181024151213]
[21]
Song, Z.; Zhou, Y.; Zhang, W.; Zhan, L.; Yu, Y.; Chen, Y.; Jia, W.; Liu, Z.; Qian, J.; Zhang, Y.; Li, C.; Liang, G. Base promoted synthesis of novel indole-dithiocarbamate compounds as potential anti-inflammatory therapeutic agents for treatment of acute lung injury. Eur. J. Med. Chem., 2019, 171, 54-65.
[http://dx.doi.org/10.1016/j.ejmech.2019.03.022] [PMID: 30909020]
[22]
Chadha, N.; Silakari, O. Indoles as therapeutics of interest in medicinal chemistry: Bird’s eye view. Eur. J. Med. Chem., 2017, 134, 159-184.
[http://dx.doi.org/10.1016/j.ejmech.2017.04.003] [PMID: 28412530]
[23]
Gaba, M.; Singh, S.; Mohan, C. Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents. Eur. J. Med. Chem., 2014, 76, 494-505.
[http://dx.doi.org/10.1016/j.ejmech.2014.01.030] [PMID: 24602792]
[24]
Briguglio, I.; Piras, S.; Corona, P.; Gavini, E.; Nieddu, M.; Boatto, G.; Carta, A. Benzotriazole: An overview on its versatile biological behavior. Eur. J. Med. Chem., 2015, 97, 612-648.
[http://dx.doi.org/10.1016/j.ejmech.2014.09.089] [PMID: 25293580]
[25]
George, S.; Parameswaran, M.K.; Ravi, T.K. Synthesis and evaluation of the biological activities of some 3-{[5-(6-methyl-4-aryl-2-oxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl)-1, 3, 4-oxadiazol-2-yl]-imino}-1, 3-dihydro-2H-indol-2-one derivatives. Acta Pharm., 2008, 58(1), 119-129.
[http://dx.doi.org/10.2478/v10007-007-0050-4] [PMID: 18337213]
[26]
Ebrahimzadeh, M.A.; Nabavi, S.F.; Nabavi, S.M. Antioxidant activities of methanol extract of Sambucus ebulus L. flower. Pak. J. Biol. Sci., 2009, 12(5), 447-450.
[http://dx.doi.org/10.3923/pjbs.2009.447.450] [PMID: 19579986]
[27]
Alam, M.N.; Bristi, N.J.; Rafiquzzaman, M. Review on in vivo and in vitro methods evaluation of antioxidant activity. Saudi Pharm. J., 2013, 21(2), 143-152.
[http://dx.doi.org/10.1016/j.jsps.2012.05.002] [PMID: 24936134]
[28]
Banu, S.; Arunachalam, G.; Jayaveera, K.; Ashoka Babu, V.; Premakumari, K. Estimation of total phenolic content and in vitro antioxidant activity of Barleria Montana. Pharm. Lett., 2011, 3(4), 178.
[29]
Deep, A.; Jain, S.; Sharma, P.C. Synthesis and anti-inflammatory activity of some novel biphenyl-4-carboxylic acid 5-(arylidene)-2-(aryl)-4-oxothiazolidin-3-yl amides. Acta Pol. Pharm., 2010, 67(1), 63-67.
[PMID: 20210080]
[30]
Sonawane, L.; Bari, S. Synthesis and spectral characterization of some novel N-substituted 2, 4-thiazolidinedione. International Journal of Biological Chemistry, 2011, 5(1), 68-74.
[http://dx.doi.org/10.3923/ijbc.2011.68.74]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy